Linda Hsieh-Wilson, PhD - Professor of Chemistry, California Institute of Technology. She is also an adjunct professor at the Semel Institute for Neuroscience and Human Behavior at the University of California, Los Angeles. Dr.Hsieh-Wilson received her Bachelor's degree in chemistry at Yale University. She completed her Ph.D. in 1996 at the University of California, Berkeley, where she worked with Peter G. Schultz on antibody-based catalysis and post doctoral training at the Rockefeller University with Nobel Laureate Paul Greengard until 2000. Dr. Hsieh-Wilson's interests are at the interface between organic chemistry and neuroscience, she investigates how glycans affect the structure and function of proteins. Her laboratory has developed a novel methods targeting a dynamic form of glycosylation, O-GlcNAc. Her work with glycosaminoglycan microarrays has significantly advanced an understanding of specific sulfated glycosaminoglycans in neuronal communication as well as advanced the field of chemical biology.
Milind Javle, MD - Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center. He has served in the past as Assistant Professor of Medical Oncology at Roswell Park Cancer Institute and has been a faculty member at MD Anderson Cancer Center since 2007 in the GI Medical Oncology Division. Dr.Javle research interests include cellular and molecular mechanisms of Gastrointestinal cancers, identification of molecular subtypes of pancreatic and biliary cancers and development of novel cancer therapeutics. His research interests are also focusted on comprehensive genomic profiling of GI cancers and understanding of the genomic alterations that are frequently present in biliary tract cancers highlighting their heterogeneity. Dr. Javle has been involved as Principal Investigator and Investigator in a number of academic and clincial studies supported by NIH, NIH/NCI, Novartis and Merk. He is a member of Editorial Board of Journal of Hematology & Oncology.
Hilary Calvert, MD, FRCP, FMedSci - Emeritus Professor of Cancer Therapeutics and Director of Anticancer Drug Discovery and Development Director at the UCL Cancer Institute at University College London. Throughout his extensive and hugely successful career spanning over 35 years, Hilary has worked in a range of anticancer drug development projects, including the introduction of carboplatin into clinical practice, the development of a dosing formula based on its pharmacokinetics and its subsequent clinical development in ovarian cancer. Hilary and his team also discovered a “first in class” inhibitor of PARP. Under Hilary’s leadership, AstraZeneca developed inhibitors of thymidylate synthase, leading to the licensing of Tomudex (raltitrexed) by AstraZeneca. The consequent interest generated in this class of drugs led to the development of pemetrexed (Alimta) by Eli Lilly. Hilary has been awarded numerous awards in recognition of his significant impact to the field of oncology including Pfizer Research Innovation Award, British Oncological Association / Pfizer Lifetime Achievement Award, European Society of Medical Oncology Lifetime Achievement Award, co-recipient of the CR UK Team Award for his work on PARP inhibitors. He is an author on over 240 scientific papers, and is a co-editor of the Handbook of Drug Development.
Dusko Ilic, MD, PhD – Senior Lecturer in Stem Cell Science, and Head of the Induced Pluripotent Stem Cell Core Facility at King's College London (KCL) and Guy's Hospital. At Guy's, he is Head of the Assisted Conception Unit's Human Embryonic Laboratories. He is also a member of the Editorial Board of the journal Regenerative Medicine. Dr Ilic obtained his MD degree at the University of Belgrade, PhD at the Tokyo University, Japan, and postdoctoral training at UCSF. Before joining King’s College School of Medicine in London as a Senior Lecturer in Stem Cell Science, he held positions of Adjunct Associate Professor at the University of California at San Francisco, Consultant at the Veteran Affairs Medical Center, San Francisco, and the Director of R&D at StemLifeLine, a California-licensed stem cell company. His work significantey contributed to understanding of molecular mechanisms of cancer development, cell motility, signal trusduction and intracellular protein-tyrosine kinases. Dr. Ilic current research focus is on in human embryonic stem (hES) cells, induced pluripotent stem (iPS) cells, cancer stem cells, and regenerative medicine.
Mark Boldin, MD, PhD – Assistant Professor at the Department of Molecular and Cellular Biology, City of Hope National Medical Center. Dr. Boldin received his medical degree from the Russian National Research Medical University in Moscow in 1992 and his Ph.D. in Molecular Biology from the Weizmann Institute of Science in Rehovot in 1999. He has been trained as a postdoctoral fellow and then as a staff scientist in the laboratory of Professor David Baltimore at the California Institute of Technology in Pasadena. Before joining City of Hope in 2011, Mark Boldin served as a Senior Scientist at Regulus Therapeutics. Dr. Boldin research focus is on better understanding of inflammation, the molecular mechanisms that govern malignant transformation of immune cells can potentially provide new and innovative means to diagnose and treat various blood cancers.Dr.Boldin has published a number of outstanding scientific papers in peer-reviewed journals and holds a number of patents and patent applications.
Scientific and Clinical Advisory Board
your partner in personalized medicine